Novo Nordisk Shares Under Pressure from Marketing Spend and Competitive Fears

Novo Nordisk DK0062498333

Investor sentiment toward Novo Nordisk turned negative this week, with the Danish pharmaceutical giant's shares declining 4.2% to $60.28 in New York trading on Wednesday. The sell-off reflects growing concerns over the company's soaring expenditures to defend its market position and the potential for shrinking profitability in its key product segment.

A significant factor behind the market's apprehension is the substantial disparity in promotional spending between Novo Nordisk and its main competitor. During the first nine months of 2025, the company channeled approximately $500 million into U.S. advertising for its weight-loss and diabetes drugs, Wegovy and Ozempic. This investment starkly contrasts with the roughly $214 million spent by rival Eli Lilly to market its competing treatments, Zepbound and Mounjaro, over the same period.

Market analysts interpret this spending gap as a defensive move, suggesting Novo Nordisk must commit far greater capital to maintain its leadership against intensifying competition. This pressure on operating margins is a primary source of rising investor skepticism.

Restructuring and Price War Warnings

Compounding these worries are internal preparations for a leaner operational structure. According to recent media reports, Novo Nordisk is planning workforce reductions affecting up to 9,000 positions. This strategic move signals management's shift towards stricter cost control in anticipation of more challenging market conditions.

Furthermore, a stark warning from the company's chairman regarding an impending price war in the lucrative GLP-1 drug segment has unsettled the market. This official statement fuels fears that the historically high margins in this category may erode more rapidly than previously forecast.

Key Pressure Points for Novo Nordisk:
* Marketing expenses nearly double those of key competitor Eli Lilly
* Explicit warning of potential price erosion in the GLP-1 market
* Planned reduction of around 9,000 jobs
* Current P/E ratio of approximately 17.5, notably below its five-year average

Regulatory Approval Fails to Lift Sentiment

A recent positive development has been largely overshadowed by these broader concerns. The U.S. Food and Drug Administration (FDA) granted approval for an oral version of Wegovy, aimed at weight management and cardiovascular risk reduction. The distribution strategy involves partnerships with major retailers like Amazon and Costco, as well as telemedicine providers.

While this pill form expands the product portfolio and could improve patient accessibility, the market has largely ignored this news. The approval's impact is being muted by looming competitive threats, including potential generics in markets such as India, and ongoing antitrust investigations in the United States.

All Eyes on February Earnings Report

The next critical milestone for investors will be the release of Novo Nordisk's fourth-quarter and full-year 2025 results, scheduled for February 4, 2026. Market experts are anticipating earnings per share of $0.90 on revenue of about $11.97 billion for the quarter. However, the primary focus will be the company's financial guidance for the full 2026 fiscal year, which is expected to be the decisive factor for the stock's near-term trajectory.